Direct Oral Anticoagulant Use in Atypical Thrombosis-Related Conditions.

CONCLUSIONS: Until more evidence from the ongoing clinical trials is available, DOACs may not be favorable add-on therapy in ACS patients receiving standard antiplatelet therapy but may be alternative to warfarin in preventing or treating thrombosis in low-risk APLAS patients as well as in cases of CAT in which patients have to be managed with warfarin.
PMID: 28918657 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - September 1, 2017 Category: Drugs & Pharmacology Authors: Chang C, Hoyos M, Owusu Y, Elewa H Tags: Ann Pharmacother Source Type: research